Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SVRA Stock 12 Month Forecast
Average Price Target
$10.43
▲(94.59% Upside)
| Highest Price Target$16.00 | Average Price Target$10.43 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$11
Buy
105.22%
Upside
Reiterated
11/20/25
Savara's MOLBREEVI: Promising Potential in APAP Market with Strategic Expert EngagementWe will host Dr. Ali Ataya, MD (bio below) to discuss SVRA's MOLBREEVI and its commercial potenal in treang Proteinosis (APAP) on 10am ET. Broad discussion of the APAP market and current treatment paradigm Overview of MOLBREEVI's clinical data (safety/efficacy) Commercial potenal of SVRA's MOLBREEVI Please email Rob Fromberg or Mike Mills to RSVP. Rob and Mike can also provide a replay link and transcript for those who cannot make the live call. Let us know if there are specific quesons you would like asked! KOL Biography Dr. Ataya is an associate professor of medicine in the Care & Sleep Medicine, director of the the HHT and Rare Lung Disease Program.
H.C. Wainwright
$8
Buy
49.25%
Upside
Reiterated
11/14/25
Savara's Strategic Positioning and Market Readiness for Molbreevi's Potential LaunchValuation and Risks. Our price target of $8 is based on an equally weighted composite of: (a) $9.14 per share, as a 25x multiple of taxed and diluted $1.01 discounted back to and (b) an NPV of $7.72 per share, discounted cash flow analysis using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage biotechnology company.
Oppenheimer
$8→$9
Buy
67.91%
Upside
Reiterated
11/14/25
Citizens JMP
$8→$11
Buy
105.22%
Upside
Reiterated
10/23/25
Wells Fargo
$7
Buy
30.60%
Upside
Reiterated
10/17/25
We are maintaining the current ratings, price targets, and estimates.
Guggenheim
$8→$11
Buy
105.22%
Upside
Reiterated
09/08/25
Piper Sandler
$16
Buy
198.51%
Upside
Reiterated
09/03/25
Evercore ISI
$2
Hold
-62.69%
Downside
Reiterated
08/04/25
Jefferies
$8.5
Buy
58.58%
Upside
Reiterated
03/26/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$11
Buy
105.22%
Upside
Reiterated
11/20/25
Savara's MOLBREEVI: Promising Potential in APAP Market with Strategic Expert EngagementWe will host Dr. Ali Ataya, MD (bio below) to discuss SVRA's MOLBREEVI and its commercial potenal in treang Proteinosis (APAP) on 10am ET. Broad discussion of the APAP market and current treatment paradigm Overview of MOLBREEVI's clinical data (safety/efficacy) Commercial potenal of SVRA's MOLBREEVI Please email Rob Fromberg or Mike Mills to RSVP. Rob and Mike can also provide a replay link and transcript for those who cannot make the live call. Let us know if there are specific quesons you would like asked! KOL Biography Dr. Ataya is an associate professor of medicine in the Care & Sleep Medicine, director of the the HHT and Rare Lung Disease Program.
H.C. Wainwright
$8
Buy
49.25%
Upside
Reiterated
11/14/25
Savara's Strategic Positioning and Market Readiness for Molbreevi's Potential LaunchValuation and Risks. Our price target of $8 is based on an equally weighted composite of: (a) $9.14 per share, as a 25x multiple of taxed and diluted $1.01 discounted back to and (b) an NPV of $7.72 per share, discounted cash flow analysis using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage biotechnology company.
Oppenheimer
$8→$9
Buy
67.91%
Upside
Reiterated
11/14/25
Citizens JMP
$8→$11
Buy
105.22%
Upside
Reiterated
10/23/25
Wells Fargo
$7
Buy
30.60%
Upside
Reiterated
10/17/25
We are maintaining the current ratings, price targets, and estimates.
Guggenheim
$8→$11
Buy
105.22%
Upside
Reiterated
09/08/25
Piper Sandler
$16
Buy
198.51%
Upside
Reiterated
09/03/25
Evercore ISI
$2
Hold
-62.69%
Downside
Reiterated
08/04/25
Jefferies
$8.5
Buy
58.58%
Upside
Reiterated
03/26/25
Best Analysts Covering Savara
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+9.63%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +9.63% per trade.
3 Months
xxx
Success Rate
6/9 ratings generated profit
Average Return
+7.94%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +7.94% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+16.91%
reiterated a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +16.91% per trade.
2 Years
xxx
Success Rate
7/9 ratings generated profit
Average Return
+14.61%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +14.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SVRA Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
9
11
9
11
12
Buy
0
0
0
0
0
Hold
3
4
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
15
10
12
12
Each month's total comprises the sum of three months' worth of ratings.
SVRA Financial Forecast
SVRA Stock Forecast FAQ
What is SVRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Savara’s 12-month average price target is 10.43.
What is SVRA’s upside potential, based on the analysts’ average price target?
Savara has 94.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SVRA a Buy, Sell or Hold?
Savara has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Savara’s price target?
The average price target for Savara is 10.43. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $7.00. The average price target represents 94.59% Increase from the current price of $5.36.
The highest analyst price target is $16.00 ,the lowest forecast is $7.00. The average price target represents 94.59% Increase from the current price of $5.36.
What do analysts say about Savara?
Savara’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of SVRA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.